References
- Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311:1901−1911.
- Tian K, Shibata-Germanos S, Pahlitzsch M, Cordeiro MF. Current perspective of neuroprotection and glaucoma. Clin Ophthalmol 2015;9:2109−2118.
- Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998;12:225−241.
- Yoles E, Wheeler LA, Schwartz M. α2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999;40:65−73.
- Lambert WS, Ruiz L, Crish SD, Wheeler LA, Calkins D. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener 2011;6:4.
- Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res. 1992;24:213−219.
- Berlie JR, Iversen LJ, Blaxall HS, Cooley ME, Chacko DM, Bylund DB. Alpha-2 adrenergic receptors in the bovine retina. Presence of only the alpha-2D subtype. Invest Ophthalmol Vis Sci 1995;36:1885−1892.
- Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003;48:S47−S51.
- Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol 2011;151:671−681.
- Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 2001;108:784–787.
- Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41:S9–S18.
- Takamura Y, Tomomatsu T, Matsumura T, Takihara Y, Kozai S, Arimura S, Yokota S, Inatani M. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans. J Ocul Pharmacol Ther 2015;31:282−285.
- Kent AR, King L, Bartholomew LR. Vitreous concentration of topically applied brimonidine-Purite 0.15%. J Ocul Pharmacol Ther. 2006;22:242−246.
- Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos 2002;30:421−429.
- Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010;12:348−360.
- Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995;23:708−712.
- Lee AJ, McCluskey P. Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin Ophthalmol. 2008;2:545−555.
- Potts AM. The reaction of uveal pigment in vitro with polycyclic compounds. Invest Ophthalmol Vis Sci 1964;3:405−416.
- Buszman E, Rózańska R. Interaction of thioridazine with ocular melanin in vitro. Acta Pol Pharm 2003;60:257−261.
- Koeberle MJ, Hughes PM, Skellern GG, Wilson CG. Binding of memantine to melanin: influence of type of melanin and characteristics. Pharm Res 2003;20:1702−1709.
- Durairaj C, Chastain JE, Kompella UB. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res 2012;98:23−27.
- Stepien KB, Wilczok T. Studies of the mechanism of chloroquine binding to synthetic DOPA-melanin. Biochem Pharmacol 1982;31:3359−3365.